Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2010 (2010), Article ID 683875, 7 pages
http://dx.doi.org/10.1155/2010/683875
Review Article

B7-H3 and Its Role in Antitumor Immunity

Chirurgische Klinik und Poliklinik, Klinikum Rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675 München, Germany

Received 29 June 2010; Revised 16 September 2010; Accepted 19 October 2010

Academic Editor: C. D. Pauza

Copyright © 2010 Martin Loos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. K. Abbas, “The control of T cell activation vs. tolerance,” Autoimmunity Reviews, vol. 2, no. 3, pp. 115–118, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Chen, “Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity,” Nature Reviews Immunology, vol. 4, no. 5, pp. 336–347, 2004. View at Google Scholar · View at Scopus
  3. R. J. Greenwald, G. J. Freeman, and A. H. Sharpe, “The B7 family revisited,” Annual Review of Immunology, vol. 23, pp. 515–548, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. M. Loos, N. A. Giese, and N. A. Giese, “Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer,” Cancer Letters, vol. 268, no. 1, pp. 98–109, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. J. Konishi, K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita, and M. Nishimura, “B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression,” Clinical Cancer Research, vol. 10, no. 15, pp. 5094–5100, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. Y. Liu, B. Zeng, Z. Zhang, Y. Zhang, and R. Yang, “B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer,” Clinical Immunology, vol. 129, no. 3, pp. 471–481, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. H. Ghebeh, S. Mohammed, and S. Mohammed, “The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors,” Neoplasia, vol. 8, no. 3, pp. 190–198, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. R. H. Thompson, M. D. Gillett, and M. D. Gillett, “Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 49, pp. 17174–17179, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. E. J. Small, N. S. Tchekmedyian, B. I. Rini, L. Fong, I. Lowy, and J. P. Allison, “A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer,” Clinical Cancer Research, vol. 13, no. 6, pp. 1810–1815, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. E. D. Kwon, B. A. Foster, A. A. Hurwitz, C. Madias, J. P. Allison, N. M. Greenberg, and M. B. Burg, “Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 26, pp. 15074–15079, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. M. R. Theoret, P. M. Arlen, M. Pazdur, W. L. Dahut, J. Schlom, and J. L. Gulley, “Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer,” Clinical Genitourinary Cancer, vol. 5, no. 5, pp. 347–350, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. C. I. Liakou, A. Kamat, and A. Kamat, “CTLA-4 blockade increases IFNγ-producing CD4+ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 39, pp. 14987–14992, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. R. H. Thompson, J. P. Allison, and E. D. Kwon, “Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer,” Urologic Oncology, vol. 24, no. 5, pp. 442–447, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. J. A. Blansfield, K. E. Beck, and K. E. Beck, “Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer,” Journal of Immunotherapy, vol. 28, no. 6, pp. 593–598, 2005. View at Google Scholar · View at Scopus
  15. J. Yuan, S. Gnjatic, and S. Gnjatic, “CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 51, pp. 20410–20415, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. D. O'Mahony, J. C. Morris, and J. C. Morris, “A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy,” Clinical Cancer Research, vol. 13, no. 3, pp. 958–964, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. S. M. Ansell, S. A. Hurvitz, and S. A. Hurvitz, “Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma,” Clinical Cancer Research, vol. 15, no. 20, pp. 6446–6453, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. A. I. Chapoval, J. Ni, and J. Ni, “B7-H3: a costimulatory molecule for T cell activation and IFN-γ production,” Nature Immunology, vol. 2, no. 3, pp. 269–274, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. R. Castriconi, A. Dondero, and A. Dondero, “Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 34, pp. 12640–12645, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. P. Steinberger, O. Majdic, and O. Majdic, “Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains,” Journal of Immunology, vol. 172, no. 4, pp. 2352–2359, 2004. View at Google Scholar · View at Scopus
  21. M. Hashiguchi, H. Kobori, P. Ritprajak, Y. Kamimura, H. Kozono, and M. Azuma, “Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 30, pp. 10495–10500, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. J. Klesney-Tait, I. R. Turnbull, and M. Colonna, “The TREM receptor family and signal integration,” Nature Immunology, vol. 7, no. 12, pp. 1266–1273, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. J. Leitner, C. Klauser, and C. Klauser, “B7-H3 is a potent inhibitor of human T-cell activation: no evidence for B7-H3 and TREML2 interaction,” European Journal of Immunology, vol. 39, no. 7, pp. 1754–1764, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. Y. Sun, Y. Wang, J. Zhao, M. Gu, R. Giscombe, A. K. Lefvert, and X. Wang, “B7-H3 and B7-H4 expression in non-small-cell lung cancer,” Lung Cancer, vol. 53, no. 2, pp. 143–151, 2006. View at Publisher · View at Google Scholar · View at PubMed
  25. M. Loos, D. M. Hedderich, and D. M. Hedderich, “Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer,” BMC Cancer, vol. 9, article 463, 2009. View at Publisher · View at Google Scholar · View at PubMed
  26. X.-P. Wu, J.-T. Jiang, and J.-T. Jiang, “Relationship between co-stimulatory molecue B7-H3 expression and gastric carcinoma histology and prognosis,” World Journal of Gastroenterology, vol. 12, no. 3, pp. 457–459, 2006. View at Google Scholar · View at Scopus
  27. X. Zang, P. S. Sullivan, and P. S. Sullivan, “Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas,” Modern Pathology, vol. 23, no. 8, pp. 1104–1112, 2010. View at Publisher · View at Google Scholar · View at PubMed
  28. P. L. Crispen, Y. Sheinin, and Y. Sheinin, “Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma,” Clinical Cancer Research, vol. 14, no. 16, pp. 5150–5157, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. J. Sun, L. -J. Chen, and L. -J. Chen, “Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma,” Cancer Immunology, Immunotherapy, vol. 59, no. 8, pp. 1163–1171, 2010. View at Publisher · View at Google Scholar · View at PubMed
  30. S. A. Boorjian, Y. Sheinin, and Y. Sheinin, “T-Cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival,” Clinical Cancer Research, vol. 14, no. 15, pp. 4800–4808, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. T. J. Roth, Y. Sheinin, and Y. Sheinin, “B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy,” Cancer Research, vol. 67, no. 16, pp. 7893–7900, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. L. Wang, C. C. Fraser, and C. C. Fraser, “B7-H3 promotes acute and chronic allograft rejection,” European Journal of Immunology, vol. 35, no. 2, pp. 428–438, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. O. Nagashima, N. Harada, and N. Harada, “B7-H3 contributes to the development of pathogenic Th2 cells in a murine model of asthma,” Journal of Immunology, vol. 181, no. 6, pp. 4062–4071, 2008. View at Google Scholar · View at Scopus
  34. L. Luo, A. I. Chapoval, and A. I. Chapoval, “B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells,” Journal of Immunology, vol. 173, no. 9, pp. 5445–5450, 2004. View at Google Scholar · View at Scopus
  35. X. Sun, M. Vale, E. Leung, J. R. Kanwar, R. Gupta, and G. W. Krissansen, “Mouse B7-H3 induces antitumor immunity,” Gene Therapy, vol. 10, no. 20, pp. 1728–1734, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. C. M. Lupu, C. Eisenbach, A. D. Lupu, M. A. Kuefner, B. Hoyler, W. Stremmel, and J. Encke, “Adenoviral B7-H3 therapy induces tumor specific immune responses and reduces secondary metastasis in a murine model of colon cancer,” Oncology reports, vol. 18, no. 3, pp. 745–748, 2007. View at Google Scholar · View at Scopus
  37. L. Ma, L. Luo, and L. Luo, “Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy,” Journal of Hepatology, vol. 46, no. 1, pp. 98–106, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. W.-K. Suh, B. U. Gajewska, and B. U. Gajewska, “The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses,” Nature Immunology, vol. 4, no. 9, pp. 899–906, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. D. V. R. Prasad, T. Nguyen, Z. Li, Y. Yang, J. Duong, Y. Wang, and C. Dong, “Murine B7-H3 is a negative regulator of T cells,” Journal of Immunology, vol. 173, no. 4, pp. 2500–2506, 2004. View at Google Scholar · View at Scopus
  40. A. Fukushima, T. Sumi, and T. Sumi, “B7-H3 regulates the development of experimental allergic conjunctivitis in mice,” Immunology Letters, vol. 113, no. 1, pp. 52–57, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. K. Mahnke, S. Ring, and S. Ring, “Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation,” European Journal of Immunology, vol. 37, no. 8, pp. 2117–2126, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. G. Zhang, Y. Xu, X. Lu, H. Huang, Y. Zhou, B. Lu, and X. Zhang, “Diagnosis value of serum B7-H3 expression in non-small cell lung cancer,” Lung Cancer, vol. 66, no. 2, pp. 245–249, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. X. Zang, R. H. Thompson, and R. H. Thompson, “B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 49, pp. 19458–19463, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. S. A. Boorjian, Y. Sheinin, P. L. Crispen, C. M. Lohse, B. C. Leibovich, and E. D. Kwon, “T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangioleiomyomatosis,” Urology, vol. 74, no. 6, pp. 1359–1364, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. A. Gregorio, M. V. Corrias, and M. V. Corrias, “Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule,” Histopathology, vol. 53, no. 1, pp. 73–80, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. A. S. Parker, M. G. Heckman, and M. G. Heckman, “Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer,” International Journal of Radiation Oncology, Biology, Physics. In press. View at Publisher · View at Google Scholar · View at PubMed
  47. I. Yamato, M. Sho, and M. Sho, “Clinical importance of B7-H3 expression in human pancreatic cancer,” British Journal of Cancer, vol. 101, no. 10, pp. 1709–1716, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. I. Tirapu, E. Huarte, and E. Huarte, “Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma,” Cancer Research, vol. 66, no. 4, pp. 2442–2450, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. K. H. Yi and L. Chen, “Fine tuning the immune response through B7-H3 and B7-H4,” Immunological Reviews, vol. 229, no. 1, pp. 145–151, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. T. Sun, Z. Hu, H. Shen, and D. Lin, “Genetic polymorphisms in cytotoxic T-lymphocyte antigen 4 and cancer: the dialectical nature of subtle human immune dysregulation,” Cancer Research, vol. 69, no. 15, pp. 6011–6014, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. M. Z. Dewan, A. E. Galloway, N. Kawashima, J. K. Dewyngaert, J. S. Babb, S. C. Formenti, and S. Demaria, “Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody,” Clinical Cancer Research, vol. 15, no. 17, pp. 5379–5388, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. A. V. Maker, G. Q. Phan, and G. Q. Phan, “Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study,” Annals of Surgical Oncology, vol. 12, no. 12, pp. 1005–1016, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. F. S. Hodi, M. C. Mihm, and M. C. Mihm, “Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 8, pp. 4712–4717, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. H. J. J. van der Vliet, H. B. Koon, and H. B. Koon, “Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer,” Clinical Cancer Research, vol. 13, no. 7, pp. 2100–2108, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. J. R. Brahmer, C. G. Drake, and C. G. Drake, “Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates,” Journal of Clinical Oncology, vol. 28, no. 19, pp. 3167–3175, 2010. View at Publisher · View at Google Scholar · View at PubMed